Advertisement


Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

2023 ASCO Annual Meeting

Advertisement

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Alberto Bossi, MD: PEACE-1 is a randomized Phase III trial with four arms that has been designed some 11 years ago in order to study a very precise population of patients, which is patients presenting de novo of diagnosis with metastatic prostate cancer. There has been a huge landscape movement in the last years concerning this subgroup of patients and PEACE-1 has specifically been designed to answer two questions. First of all, the benefit of abiraterone on top of standard of care, and second, to detect if any benefit of local radiotherapy, prostate radiotherapy would be important for those patients, so two questions, four arms. Standard of care has been updated during the inclusion period of the study because we had some new evidence coming from the literature, and so the use of chemotherapy, docetaxel, has been at first introduced and compulsory at the end of the trial, four arms, so that have been compared and two main endpoints, radiographic progression-free survival and overall survival. Then a list of secondary endpoints, which we also discuss. What we discovered, in terms of overall survival, no difference between the use of local radiotherapy in those patients, both in the low volume population so patients presenting with low volume metastatic disease as in the high volume population, patients presenting with high burden of metastatic disease, no impact of radiotherapy. But using radiotherapy translates in a better radiographic progression-free survival, which was the second co-primary endpoint. We then had a list of secondary endpoints and we made studies on three of them. First, castration resistant state, and we discovered that giving radiotherapy in the prostate on those patients delays the onset of the castration resistant state, and this in a significant way. And second, that also in terms of secondary events locally in the prostate, radiotherapy may delay the need of a secondary treatment for those patients. Altogether, I think that in terms of quality of life for our patients these are very important outcomes. What's next? Well, first we have to dig into those data with much more details. There are still some open questions there. You are probably aware of the result of the STAMPEDE trial, the English trial which has exactly done the same as our trial and that has shown an improvement in overall survival, why our data do not show the same, so this is something we will try to dig later on. And secondary, there are a list of other endpoints which we also will try to study more details. The secondary endpoints are also important, especially in terms of quality of life for our patients. What is reassuring, and this is the end, what is reassuring is that no added toxicity was due to radiotherapy in the prostate and I think that this is very good and reassuring information for our patients and their family.

Related Videos

Gynecologic Cancers
Immunotherapy

Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy

Bradley J. Monk, MD, of the University of Arizona, Phoenix, and Creighton University, discusses phase III findings from the KEYNOTE-826 study of overall survival results in patients with persistent, recurrent, or metastatic cervical cancer. Study participants received first-line treatment of pembrolizumab plus chemotherapy, with or without bevacizumab, which reduced the risk of death by up to 40% in three different subsets of patients (Abstract 5500).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, both of Dana-Farber Cancer Institute, discuss an individual patient-data analysis of randomized trials from the ICECAP collaborative. A PSA nadir of ≥ 0.1 ng/mL within 6 months after radiotherapy completion was prognostic for prostate cancer–specific, metastasis-free, and overall survival in patients receiving radiotherapy plus androgen-deprivation therapy for localized prostate cancer. These findings may help identify patients for therapy de-escalation trials (Abstract 5002).

Myelodysplastic Syndromes

Amer Methqal Zeidan, MBBS, MHS, on Myelodysplastic Syndromes: New Data From the IMerge Study of Imetelstat

Amer Methqal Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, discusses phase III findings on the first-in-class telomerase inhibitor imetelstat, which was given to patients with heavily transfusion-dependent non-del(5q) lower-risk myelodysplastic syndromes that are resistant to erythropoiesis-stimulating agents. Imetelstat resulted in a significant and sustained red blood cell (RBC) transfusion independence in 40% of these heavily transfused patients. The response was also durable and accompanied by an impressive median hemoglobin rise of 3.6 g/dL, and seen in patients with and without ring sideroblasts. Importantly, reduced variant allele frequency was observed in the most commonly mutated myeloid genes which correlated with duration of transfusion independence and hemoglobin rise, therefore suggesting a disease-modifying potential of this agent (Abstract 7004).

Lung Cancer

Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss the use of tumor treating fields therapy, in which electric fields disrupt processes critical for cancer cell viability. Already approved by the FDA to treat glioblastoma and mesothelioma, the treatment has extended overall survival in this phase III study of patients with metastatic non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, without exacerbating systemic toxicities (Abstract LBA9005).

Breast Cancer

Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative early breast cancer. When added to standard-of-care endocrine therapy, ribociclib improved invasive disease–free survival with a well-tolerated safety profile (Abstract LBA500).

Advertisement

Advertisement




Advertisement